Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Hims & Hers between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareho ...

MINNEAPOLIS, Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:2025 Wells Fargo Healthcare ConferenceSeptember 3, 202510:15 AM EDTBaird 2025 Global Healthcare ConferenceSeptember 9, 20259:05 AM EDTMorgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 10, 202510:45 AM EDTA live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://invest ...

#tedxmaharashtracollege #MaharashtraCollege #DrwasimPhoplunkar #oncologist Dr. Wasim S. Phoplunkar is a globally acclaimed Radiation Oncologist , with 25+ years of global experience across India, Canada and Saudi Arabia. From cutting-edge treatments like IMRT, IGRT & RapidArc to humanizing the cancer care journey, Dr. Phoplunkar is redefining healing with both technology and compassion This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn ...

Medallion is setting up a national clearinghouse to streamline a healthcare credentialing process that costs more than $1 billion annually. https://t.co/sC9zEPeyZF https://t.co/AUTUgNz0Cv ...

MIT report last week said that 95% of companies AI pilot programs have not rapidly boosted revenues. But Morgan Stanley is playing the long game here, writing the S&P 500 alone could see as much as $16 trillion in market value gains as AI adoption continues over the next few years. So which sectors will see the biggest gains of that $16 trillion.Joining me now is Stephen Bird, global head of thematic research and sustainability research over at Morgan Stanley. Stephen, this is a fascinating discussion becau ...

Hello. In the pursuits of our goals, we often begin from nothing or closer to nothing. But what if I tell you we could kickstart from the halfway mark.Yes, believe you can. You are halfway there. When I say belief, when I say faith, it is the light that makes our life bright even during the darkest times.We all walk through life with questions, some big and some small. Questions about meaning, purpose, and direction of our life. At times, life is clear and full of joy. At other times, it is uncertain, unpre ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Styl ...

After losing 31 pounds on a GLP-1 drug, Serena Williams is the new face of healthcare startup Ro https://t.co/f9dTJiLwYw ...

Core Insights - Renaissance Technologies is recognized as the most successful hedge fund, with its Medallion Fund achieving annualized after-fees returns of 39% from 1998 to 2021 [1] - Despite the passing of its founder Jim Simons in 2024, Renaissance's investment strategies and quarterly moves continue to attract attention from investors [1] Group 1: Palantir Technologies - Palantir remains the largest holding in Renaissance's portfolio, despite a 17% reduction in shares during Q2 [2][3] - The stock experienced a significant increase of approximately 61% from March 31 to June 30 [2] - Over the past 52 weeks, Palantir's stock has surged nearly 400%, with a forward P/E ratio exceeding 200x [3] Group 2: Robinhood Markets - Robinhood is also among the top five holdings, with a 31% reduction in shares in Q2, while the stock rose about 125% during the same period [5][6] - The stock reached an all-time high forward P/E of around 71x in early June but has since decreased to approximately 54x [6] Group 3: UnitedHealth Group - Renaissance initiated a new position in UnitedHealth Group, purchasing approximately 1.35 million shares, following Berkshire Hathaway's significant investment [7][8] - The stock trades about 15% higher than its lowest level in Q2, indicating potential value for investors [9] Group 4: NVIDIA - Renaissance made a substantial increase in its position in NVIDIA, raising shares from around 1.1 million in Q1 to 7.4 million in Q2, marking a 584% increase [10] - The decision to increase holdings may have been influenced by a reassessment of previous fears related to DeepSeek [12] - The average closing price of NVIDIA remained stable between Q1 and Q2, suggesting that price action was not the primary factor for the dramatic change in position [11] Group 5: Investment Strategies - Renaissance's investment moves highlight two strategies: taking profits on significant winners and selectively dip-buying during downturns in dominant industry players [13]

Core Insights - UnitedHealth Group Inc (UNH) and Novo Nordisk A/S (NVO) are both facing significant stock declines this year, with UNH down 38.85% YTD and NVO down 38.59% YTD, yet their strategies differ greatly [1] UnitedHealth Group Inc (UNH) - UnitedHealth trades at approximately $308, significantly below its 52-week high of $630.73, indicating market concerns regarding profitability and industry pressures [2] - The company has a market capitalization of $279.4 billion and a P/E ratio of 13.36, making it a relatively safe option for income-focused investors amid market volatility [3] - UnitedHealth offers a forward dividend yield of 2.87% with a conservative payout ratio of 36.8%, alongside a gross profit margin of 17.9% and quarterly net margins just above 3% [2][3] Novo Nordisk A/S (NVO) - Novo Nordisk is currently trading at around $54, down from its 52-week high of $139.74, but its fundamentals are strong, showcasing significant growth potential [4] - The company boasts an impressive gross margin of 83.3% and a net margin of 34.5%, which underlines its rapid revenue expansion [5] - Novo Nordisk has a forward dividend yield of 3.01% and a payout ratio of 44.3%, appealing to income investors who are willing to accept higher risk [5] Investment Strategy Considerations - For U.S. investors, the choice between UNH and NVO hinges on investment strategy: UNH is suited for those prioritizing stability and reliable income, while NVO is attractive for those seeking high growth and willing to accept volatility [6]